Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 16,275 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Condition Clear all
Withdrawn No phase listed Observational Accepts healthy volunteers

Epigenetics of TNBC in Overweight and Obese Hispanic & Non-Hispanic White Women

NCT04291950
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Needle core biopsy
Procedure
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 22, 2026, 5:11 AM EDT
Completed Phase 2 Interventional Results available

Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis

NCT02129660
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Dose 1 of glycopyrrolate, 2.0% QD, Dose 2 of glycopyrrolate, 3.0% QD, Dose 1 of glycopyrronium, 2.5% QD, Dose 2 of glycopyrronium, 3.75% QD, Vehicle
Drug · Other
Lead sponsor
Journey Medical Corporation
Industry
Eligibility
18 Years to 99 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
14
States / cities
Encinitas, California • Fremont, California • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 22, 2026, 5:11 AM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Real-time Diagnosis and Visualization of Tumor Margins in Excised Breast Specimens Using Zenith FLIM Diagnostics

NCT04683120
View directory record Official record
Conditions
Oncology, Breast Cancer, Cancer Diagnosis, Margins of Excision, Margins, Tumor-Free
Interventions
Zenith FLIM Diagnostics
Diagnostic Test
Lead sponsor
Laser LabCorp
Industry
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 22, 2026, 5:11 AM EDT
Terminated Phase 3 Interventional

Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant

NCT00324324
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
moxifloxacin hydrochloride, Placebo
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 22, 2026, 5:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Post-Treatment Surveillance in Breast Cancer: Bringing CER to the Alliance

NCT02171078
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Female only
Enrollment
34,359 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Oct 22, 2026, 5:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessment of Automated Breast Ultrasound

NCT02386176
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
40 Years to 75 Years · Female only
Enrollment
598 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Oct 22, 2026, 5:11 AM EDT
Recruiting Phase 2 Interventional

A Study of Romosozumab in People With Breast Cancer and Osteoporosis

NCT07776613
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer (MBC)
Interventions
Romosozumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 22, 2026, 5:11 AM EDT
Completed Early Phase 1 Interventional

Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa

NCT04979520
View directory record Official record
Conditions
Hidradenitis Suppurativa, Acne Inversa
Interventions
Brodalumab
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 99 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 22, 2026, 5:11 AM EDT
Completed Not applicable Interventional Results available

Mammosite Breast Brachytherapy Optimization in the Treatment of Breast Carcinoma

NCT00611624
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Mammosite brachytherapy radiation
Radiation
Lead sponsor
Yale University
Other
Eligibility
50 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 22, 2026, 5:11 AM EDT
Active, not recruiting Phase 3 Interventional

Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

NCT03997123
View directory record Official record
Conditions
Triple Negative Breast Neoplasms
Interventions
Capivasertib, Paclitaxel, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
923 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
22
States / cities
Whittier, California • Fort Myers, Florida • Miami, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 22, 2026, 5:11 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis

NCT03919435
View directory record Official record
Conditions
Granulomatosis With Polyangiitis, Wegener Granulomatosis
Interventions
Trimethoprim Sulfamethoxazole
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 22, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Results available

RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)

NCT03445650
View directory record Official record
Conditions
Sjogren-Larsson Syndrome
Interventions
ADX-102 1% Topical Dermal Cream (reproxalap), Vehicle of ADX-102 Topical Dermal Cream
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
3 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
New Haven, Connecticut • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 22, 2026, 5:11 AM EDT
Completed Phase 2 Interventional Results available

Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer

NCT01698918
View directory record Official record
Conditions
Hormone Receptor Positive Breast Cancer
Interventions
Everolimus, Letrozole, Exemestane, Alcohol-free dexamethasone mouth rinse (Stomatitis sub-study), Standard of care to treat stomatitis (Stomatitis sub-study)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • Gilbert, Arizona • Loma Linda, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Oct 22, 2026, 5:11 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms

NCT06062810
View directory record Official record
Conditions
Breast Cancer
Interventions
Raloxifene - Usual, Raloxifene - Study
Drug
Lead sponsor
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Industry
Eligibility
24 Years to 64 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 22, 2026, 5:11 AM EDT
Completed No phase listed Observational

People-Powered Medicine (PPM): Rheumatoid Arthritis Non-responders to Biologic Therapies (RANT)

NCT05447182
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 95 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 22, 2026, 5:11 AM EDT
Withdrawn Phase 2 Interventional

Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted Therapy

NCT00343759
View directory record Official record
Conditions
Breast Cancer
Interventions
Lapatinib
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 11, 2015 · Synced Oct 22, 2026, 5:11 AM EDT
Withdrawn No phase listed Observational

Predicting Breast Flap Necrosis by Spatial Frequency Domain Imaging

NCT02273076
View directory record Official record
Conditions
Disorders of Skin Grafts and Flaps
Interventions
Spatial Frequency Domain Imaging
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 22, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication

NCT00365989
View directory record Official record
Conditions
Uterine Leiomyoma, Uterine Fibroids
Interventions
ExAblate Enhanced Sonication
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
4
States / cities
La Jolla, California • Burlington, Massachusetts • Kalamazoo, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Oct 22, 2026, 5:11 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial of Drain Antisepsis After Tissue Expander Breast Reconstruction

NCT01286168
View directory record Official record
Conditions
Nonmalignant Breast Conditions, Breast Cancer
Interventions
Sodium hypochlorite (Dakin's Solution), Chlorhexidine gluconate disk, Control, Occlusive Adhesive Dressing
Device · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
2
States / cities
San Francisco, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 22, 2026, 5:11 AM EDT
Completed Not applicable Interventional

Mobile Health (mHealth) Black Women With Breast Cancer

NCT02463474
View directory record Official record
Conditions
Breast Neoplasms
Interventions
mHealth Intervention
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
21 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 22, 2026, 5:11 AM EDT
Active, not recruiting No phase listed Observational

Database Retrieval for the Comprehensive Shoulder

NCT03409718
View directory record Official record
Conditions
Osteoarthritis of the Shoulder, Avascular Necrosis, Rheumatoid Arthritis, Prior Failed Revision, Correction of Functional Deformity, Fracture of Proximal End of Humerus, Cuff Tear Arthropathy
Interventions
Biomet Comprehensive Shoulder System
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 22, 2026, 5:11 AM EDT
Terminated Phase 2 Interventional Results available

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

NCT04383210
View directory record Official record
Conditions
Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer, Lung Cancer, Head and Neck Cancer, Breast Cancer, Kidney Cancer, Colorectal Cancer, Bladder Cancer, Ovarian Cancer, Sarcoma, Gallbladder Cancer, Bile Duct Cancer, Esophageal Cancer, Uterine Cancer, Cholangiocarcinoma, Prostate Cancer
Interventions
Seribantumab
Drug
Lead sponsor
Elevation Oncology
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fountain Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 22, 2026, 5:11 AM EDT
Active, not recruiting Not applicable Interventional

Breast Margin Study: Routine Cavity Shave Margins Vs. Selective Margins Using Savi Scout®

NCT05825482
View directory record Official record
Conditions
Breast Cancer
Interventions
Arm 1 Partial mastectomy with Savi Scout® localization and shave margins., Arm 2 Partial mastectomy with Savi Scout® localization and selective shave margins.
Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 22, 2026, 5:11 AM EDT
Completed Phase 2 Interventional

Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic Melanoma

NCT00203879
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
MAGE-3/Melan-A/gp100/NA PBMC, rhIL-12 (drug), MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 22, 2026, 5:11 AM EDT